Neuropsychiatric complications and associated management in adolescent and young adult cancer survivors: An All of Us study.
All of Us
adolescent and young adult cancer
matched controls
neuropsychiatric
past medical history
survivor
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
29
09
2023
received:
15
06
2023
accepted:
15
10
2023
pubmed:
30
10
2023
medline:
30
10
2023
entrez:
30
10
2023
Statut:
ppublish
Résumé
About 4.5% of new cancer cases affect adolescent and young adult aged between 15 and 39 years in the United States (US). However, the effect of neuropsychiatric conditions on long-term adolescent and young adult cancer (AYAC) survivors has not been formally investigated. Thus, the impact and management of late neuropsychiatric complications in AYAC survivors compared to non-cancer-matched controls (NCMC) in the US were evaluated using the All of Us (AoU) Research Program. Participants in the AoU Controlled Tier Dataset (v6) diagnosed with cancer between ages 15 and 39 were identified from electronic health records and surveys. AYAC survivors were matched with NCMC using the optimal pair-matching algorithm at a 1:4 ratio. Data on past diagnoses, current follow-up care, and treatment patterns of neuropsychiatric complications were collected. Analysis was performed on 788 AYAC survivors and 3152 NCMC. AYAC survivors, with an average of 8.8 years since their first cancer diagnosis, were more likely than NCMC to receive a diagnosis of neuropathy, memory loss and epilepsy (p < 0.001). Survivors also had a higher rate of follow-up care and treatment utilization for these neurological conditions compared to NCMC (p < 0.05). Treatment utilization was highest among survivors receiving care for epilepsy (88%), and lower for neuropathy (70%), memory loss (61%), and chronic fatigue (59%). This large study reveals that AYAC survivors, on average 9 years after their cancer diagnosis, require more frequent follow-up care for neurological complications compared to non-cancer individuals. However, the management of neuropathy, memory loss, and chronic fatigue is hindered by a lack of mechanism-based effective therapies.
Sections du résumé
BACKGROUND
BACKGROUND
About 4.5% of new cancer cases affect adolescent and young adult aged between 15 and 39 years in the United States (US). However, the effect of neuropsychiatric conditions on long-term adolescent and young adult cancer (AYAC) survivors has not been formally investigated. Thus, the impact and management of late neuropsychiatric complications in AYAC survivors compared to non-cancer-matched controls (NCMC) in the US were evaluated using the All of Us (AoU) Research Program.
METHODS
METHODS
Participants in the AoU Controlled Tier Dataset (v6) diagnosed with cancer between ages 15 and 39 were identified from electronic health records and surveys. AYAC survivors were matched with NCMC using the optimal pair-matching algorithm at a 1:4 ratio. Data on past diagnoses, current follow-up care, and treatment patterns of neuropsychiatric complications were collected.
RESULTS
RESULTS
Analysis was performed on 788 AYAC survivors and 3152 NCMC. AYAC survivors, with an average of 8.8 years since their first cancer diagnosis, were more likely than NCMC to receive a diagnosis of neuropathy, memory loss and epilepsy (p < 0.001). Survivors also had a higher rate of follow-up care and treatment utilization for these neurological conditions compared to NCMC (p < 0.05). Treatment utilization was highest among survivors receiving care for epilepsy (88%), and lower for neuropathy (70%), memory loss (61%), and chronic fatigue (59%).
CONCLUSIONS
CONCLUSIONS
This large study reveals that AYAC survivors, on average 9 years after their cancer diagnosis, require more frequent follow-up care for neurological complications compared to non-cancer individuals. However, the management of neuropathy, memory loss, and chronic fatigue is hindered by a lack of mechanism-based effective therapies.
Identifiants
pubmed: 37902258
doi: 10.1002/cam4.6641
pmc: PMC10709746
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20953-20963Subventions
Organisme : NCI NIH HHS
ID : P30 CA062203
Pays : United States
Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Support Care Cancer. 2013 Jun;21(6):1597-604
pubmed: 23306935
BMC Cancer. 2021 May 31;21(1):650
pubmed: 34058985
Cancer Med. 2020 May;9(10):3417-3424
pubmed: 32202706
Cancer Med. 2023 Nov;12(22):20953-20963
pubmed: 37902258
Cancer. 2011 Jun 15;117(12):2779-90
pubmed: 21495026
J Clin Oncol. 2020 Sep 20;38(27):3161-3174
pubmed: 32673152
J Clin Oncol. 2020 Oct 1;38(28):3325-3348
pubmed: 32663120
Oncologist. 2015 Feb;20(2):186-95
pubmed: 25568146
Cancer Med. 2019 Aug;8(10):4527-4535
pubmed: 31240876
J Cancer Surviv. 2022 Oct;16(5):1065-1078
pubmed: 34424498
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Cancer. 2016 Apr 1;122(7):988-99
pubmed: 26849003
Cancer. 2012 Oct 1;118(19):4884-91
pubmed: 22688896
Stat Med. 2014 Mar 15;33(6):1057-69
pubmed: 24123228
J Neurooncol. 2018 Aug;139(1):13-21
pubmed: 29797181
Curr Pharm Des. 2017;23(42):6464-6487
pubmed: 29076421
Neurol Sci. 2019 Oct;40(10):2217-2234
pubmed: 31392641
Psychooncology. 2018 Jan;27(1):75-82
pubmed: 28568377
BMC Cancer. 2019 Feb 8;19(1):132
pubmed: 30736741
Support Care Cancer. 2019 Oct;27(10):3729-3737
pubmed: 31363906
Stud Health Technol Inform. 2015;216:574-8
pubmed: 26262116
J Natl Cancer Inst. 2021 Aug 2;113(8):997-1004
pubmed: 33839786
Oncol Nurs Forum. 2008 Sep;35(5):802-7
pubmed: 18765326
Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:69-80
pubmed: 22552982
Curr Treat Options Oncol. 2020 Feb 5;21(2):17
pubmed: 32025928
JNCI Cancer Spectr. 2022 Nov 1;6(6):
pubmed: 36321955
Psychooncology. 2022 Sep;31(9):1448-1458
pubmed: 35734846
N Engl J Med. 2019 Aug 15;381(7):668-676
pubmed: 31412182
J Natl Compr Canc Netw. 2015 Aug;13(8):1012-39
pubmed: 26285247
Cancer Med. 2023 Feb;12(4):4821-4831
pubmed: 36221816
Support Care Cancer. 2021 Jun;29(6):2821-2840
pubmed: 33231809
Support Care Cancer. 2018 Sep;26(9):3257-3266
pubmed: 29644471
Nat Rev Clin Oncol. 2015 Aug;12(8):465-80
pubmed: 26011488
J Clin Oncol. 2012 Jul 1;30(19):2393-400
pubmed: 22614977
J Natl Compr Canc Netw. 2018 Jan;16(1):66-97
pubmed: 29295883